Biogen Inc.
(NASDAQ : BIIB)

( )
BIIB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading BIIB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
5.19%82.311.8%$740.58m
BIIBBiogen Inc.
1.75%228.521.0%$544.75m
CELGCelgene Corporation
2.56%97.281.2%$463.99m
AMGNAmgen Inc.
2.66%148.421.0%$431.37m
ANACAnacor Pharmaceuticals, Inc.
-0.14%99.0615.2%$318.93m
REGNRegeneron Pharmaceuticals, Inc.
2.64%339.783.1%$318.00m
ALXNAlexion Pharmaceuticals, Inc.
2.73%114.942.5%$298.51m
ILMNIllumina, Inc.
-0.35%135.014.9%$164.34m
VRTXVertex Pharmaceuticals Incorporated
4.51%83.442.6%$130.39m
BMRNBioMarin Pharmaceutical Inc.
6.54%79.494.0%$128.15m
MDVNMedivation, Inc.
2.08%57.792.8%$121.27m
CPXXCelator Pharmaceuticals, Inc.
0.10%30.208.5%$106.05m
SRPTSarepta Therapeutics, Inc.
5.07%17.8149.4%$103.08m
AAgilent Technologies, Inc.
1.99%43.101.0%$101.23m
ACADACADIA Pharmaceuticals Inc.
4.49%31.6619.6%$96.80m

Company Profile

Biogen, Inc. is a global biotechnology company, which develops markets and manufactures therapies for people living with neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.